NIDA. People With SUDs Have Increased Risk for COVID-19 and Worse Outcomes
This Study reported;
People with a
+ substance use disorder (SUD) at any time in their lives are 1.5 times more likely to contract COVID-19 than those without an SUD, and those with a recent SUD are more than 8 times more likely.
+ People with opioid use disorder (OUD) and African Americans are at particularly high risk for COVID-19.
+ COVID-19 patients with SUDs are more likely to require hospitalization and to die from COVID-19 than those without SUD, with patients with OUD and African American patients at greatest risk.
(NIDA Notes, USA, 13.01.2021)
https://www.drugabuse.gov/news-events/nida-notes/2021/01/people-with-suds-have-increased-risk-for-covid-19-worse-outcomes
Covid Reference - 6th International Edition
Bernd-Sebastian Kamps und Christoph Hoffmann
Steinhäuser Verlag, 2021
13 January 2021. Finally, after 10 weeks, we have published the next edition of COVID Reference – The COVID Textbook (453 pages; we apologize for the delay). We dedicate this edition to Anthony Fauci who never tired of defending science.
https://covidreference.com/download
For better or for worse? A pre–post exploration of the impact of the COVID‐19 lockdown on cannabis users.
Cousijn, J., Kuhns, L., Larsen, H., and Kroon, E. (2021)
Addiction, doi.org/10.1111/add.15387.
https://onlinelibrary.wiley.com/doi/full/10.1111/add.15387
Science Denial and COVID Conspiracy Theories: Potential Neurological Mechanisms
and Possible Responses.
MILLER BL.
JAMA. 2020;324:2255-2256.
https://jamanetwork.com/journals/jama/fullarticle/2772693
Cannabis and COVID-19: Reasons for Concern.
van Laar MW, Oomen PE, van Miltenburg CJA, Vercoulen E, Freeman TP, Hall WD.
Front Psychiatry. 2020 Dec 21;11:601653. doi: 10.3389/fpsyt.2020.601653. PMID: 33408655; PMCID: PMC7779403.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779403/
Experten-Web-Konferenz. Suchtbehandlung in Covid-Zeiten: der disruptive Zwang zur Innovation
JATROS Neurologie & Psychiatrie 6/20, p. 27-29
19_J_Neuro_Kon_ÖGABS Experten-Web-Konferenz_Barth final
Impact of the COVID-19 Pandemic on Patients With Alcohol Use Disorder and Associated Risk Factors for Relapse.
Yazdi K, Fuchs-Leitner I, Rosenleitner J, Gerstgrasser NW.
Front Psychiatry. 2020 Dec 16;11:620612. doi: 10.3389/fpsyt.2020.620612. PMID: 33391060; PMCID: PMC7772314.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772314/
HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform
Bhaskaran, Krishnan et al.
The Lancet HIV, Volume 8, Issue 1, e24 - e32
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(20)30305-2/fulltext
Prioritizing incarcerated populations for COVID-19 vaccination and vaccine trials
Kronfli, Nadine et al.
EClinicalMedicine, Volume 31, 100659
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30403-X/fulltext
How Covid-19 has fueled unprecedented advances in medicine
The Covid-19 pandemic has reshaped the world of health and medicine. New vaccines are being developed at a pace once unimaginable. Telemedicine has replaced the doctor’s office for many. And artificial intelligence is predicting the patients at highest risk of growing severely ill. (stat ebook, USA, 06.01.2021)
https://www.statnews.com/covid-19-advances-in-medicine
Does opioid substitution treatment have a protective effect on the clinical manifestations of COVID-19? Comment on Br J Anaesth 2020; 125: e382-3.
Eagleton M, Stokes S, Fenton F, Keenan E.
Br J Anaesth. 2020 Nov 28:S0007-0912(20)30949-1. doi: 10.1016/j.bja.2020.11.027. Epub ahead of print. PMID: 33358041; PMCID: PMC7699021.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699021/
Down the drain: Reconsidering routine urine drug testing during the COVID-19 pandemic.
Pytell JD, Rastegar DA.
J Subst Abuse Treat. 2021 Jan;120:108155. doi: 10.1016/j.jsat.2020.108155. Epub 2020 Oct 5. PMID: 33298297; PMCID: PMC7534596.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534596/
Review of opioid risk assessment tools with the growing need for telemedicine.
Ogilvie CB, Jotwani R, Joshi J, Gulati A, Mehta N.
Pain Manag. 2020 Dec 22. doi: 10.2217/pmt-2020-0064. Epub ahead of print. PMID: 33350355.
https://www.futuremedicine.com/doi/10.2217/pmt-2020-0064
Can Kratom (Mitragyna speciosa) Alleviate COVID-19 Pain? A Case Study.
Metastasio A, Prevete E, Singh D, Grundmann O, Prozialeck WC, Veltri C, Bersani G, Corazza O.
Front Psychiatry. 2020 Nov 19;11:594816. doi: 10.3389/fpsyt.2020.594816. PMID: 33329145; PMCID: PMC7717955.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717955/
Current and Future Potential Impact of COVID-19 on Kratom (Mitragyna speciosa Korth.) Supply and Use.
Singh D, Brown PN, Cinosi E, Corazza O, Henningfield JE, Garcia-Romeu A, McCurdy CR, McMahon LR, Prozialeck WC, Smith KE, Swogger MT, Veltri C, Walsh Z, Grundmann O.
Front Psychiatry. 2020 Nov 26;11:574483. doi: 10.3389/fpsyt.2020.574483. PMID: 33324252; PMCID: PMC7726130.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726130/
The Healthy Brain and Child Development Study-Shedding Light on Opioid Exposure, COVID-19, and Health Disparities.
Volkow ND, Gordon JA, Freund MP.
JAMA Psychiatry. 2020 Dec 9. doi: 10.1001/jamapsychiatry.2020.3803. Epub ahead of print. PMID: 33295951.
https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2774000
Global Perspective and Ways to Combat Stigma Associated with COVID-19.
Adiukwu F, Bytyçi DG, Hayek SE, Gonzalez-Diaz JM, Larnaout A, Grandinetti P, Nofal M, Pereira-Sanchez V, Ransing R, Shalbafan M, Soler-Vidal J, Syarif Z, Teixeira ALS, da Costa MP, Ramalho R, Orsolini L.
Indian J Psychol Med. 2020 Nov 9;42(6):569-574. doi: 10.1177/0253717620964932. PMID: 33354085; PMCID: PMC7735248.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735248/
Monitoring drug consumption in Innsbruck during coronavirus disease 2019 (COVID-19) lockdown by wastewater analysis.
Kreidl M, Huber S, Grander J, Haslacher S, Singer K, Schlapp-Hackl M, Sorg M, Erber H, Oberacher H.
Sci Total Environ. 2020 Nov 23;757:144006. doi: 10.1016/j.scitotenv.2020.144006. Epub ahead of print. PMID: 33310574; PMCID: PMC7681035.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7681035/
Trajectories of anxiety and depressive symptoms during enforced isolation due to COVID-19 in England: a longitudinal observational study
Fancourt, Daisy et al.
The Lancet Psychiatry, Volume 0, Issue 0
https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(20)30482-X/fulltext
Rethinking Covid-19 Test Sensitivity - A Strategy for Containment.
Mina MJ, Parker R, Larremore DB.
N Engl J Med. 2020 Nov 26;383(22):e120. doi: 10.1056/NEJMp2025631. Epub 2020 Sep 30. PMID: 32997903.
https://www.nejm.org/doi/10.1056/NEJMp2025631
Impacts of COVID-19 on residential treatment programs for substance use disorder.
Pagano A, Hosakote S, Kapiteni K, Straus ER, Wong J, Guydish JR.
J Subst Abuse Treat. 2020 Dec 17:108255. doi: 10.1016/j.jsat.2020.108255. Epub ahead of print. PMID: 33375986.
https://www.journalofsubstanceabusetreatment.com/article/S0740-5472(20)30512-2/fulltext
Association of substance use disorders and drug overdose with adverse COVID-19 outcomes in New York City: January-October 2020.
Allen B, El Shahawy O, Rogers ES, Hochman S, Khan MR, Krawczyk N.
J Public Health (Oxf). 2020 Dec 26:fdaa241. doi: 10.1093/pubmed/fdaa241. Epub ahead of print. PMID: 33367823.
https://academic.oup.com/jpubhealth/advance-article/doi/10.1093/pubmed/fdaa241/6047762
Impact of COVID-19 Pandemic on Drug Overdoses in Indianapolis.
Glober N, Mohler G, Huynh P, Arkins T, O'Donnell D, Carter J, Ray B.
J Urban Health. 2020 Dec;97(6):802-807. doi: 10.1007/s11524-020-00484-0. Epub 2020 Oct 1. PMID: 33005988; PMCID: PMC7529089.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529089/
COVID-19 survey among people who use drugs in three cities in Norway.
Welle-Strand GK, Skurtveit S, Clausen T, Sundal C, Gjersing L.
Drug Alcohol Depend. 2020 Dec 1;217:108302. doi: 10.1016/j.drugalcdep.2020.108302. Epub 2020 Sep 18. PMID: 32961453; PMCID: PMC7500397.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500397/
A double-edged sword of using opioids and COVID-19: a toxicological view.
Ataei M, Shirazi FM, Lamarine RJ, Nakhaee S, Mehrpour O. A
Subst Abuse Treat Prev Policy. 2020 Dec 3;15(1):91. doi: 10.1186/s13011-020-00333-y. PMID: 33272308; PMCID: PMC7711252.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711252/
Multiple potential targets of opioids in the treatment of acute respiratory distress syndrome from COVID-19.
Cismaru CA, Cismaru GL, Nabavi SF, Ghanei M, Burz CC, Nabavi SM, Berindan Neagoe I.
J Cell Mol Med. 2020 Nov 19:10.1111/jcmm.15927. doi: 10.1111/jcmm.15927. Epub ahead of print. PMID: 33211389; PMCID: PMC7753383.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753383/
Clinical Trials for Substance Use Disorders in the Age of Covid-19.
Brezing CA, Luo SX, Mariani JJ, Levin FR. Digital
J Addict Med. 2020 Dec;14(6):e297-e302. doi: 10.1097/ADM.0000000000000733. PMID: 32956164; PMCID: PMC7647443.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7647443/
'The dual pandemic' of suicide and COVID-19: A biopsychosocial narrative of risks and prevention.
Banerjee D, Kosagisharaf JR, Sathyanarayana Rao TS.
Psychiatry Res. 2020 Nov 18:113577. doi: 10.1016/j.psychres.2020.113577. Epub ahead of print. PMID: 33229123; PMCID: PMC7672361.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672361/
Telepsychiatry and Addiction Treatment.
Mohan A, Ambekar A.
Indian J Psychol Med. 2020 Oct 6;42(5 Suppl):52S-56S. doi: 10.1177/0253717620958169. PMID: 33354065; PMCID: PMC7736732.
https://journals.sagepub.com/doi/10.1177/0253717620958169
Drug use during a pandemic: Convergent risk of novel coronavirus and invasive bacterial and viral infections among people who use drugs.
Jacka BP, Phipps E, Marshall BDL.
Int J Drug Policy. 2020 Sep;83:102895. doi: 10.1016/j.drugpo.2020.102895. Epub 2020 Jul 29. PMID: 32741718; PMCID: PMC7388892.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388892/
Seite 1 von 11